drugset / Trial / NCT00153868

A Web-based Study of Quality of Life Benefits Associated Aranesp in Anemic Patients With Cancer

NCT00153868

Phase 4 Completed 43 enrolled Dartmouth-Hitchcock Medical Center Amgen · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a web-based pilot study to evaluate the association between the treatment of anemia with darbepoetin alfa (aranesp) and the clinical benefits in symptom palliation, improved functional status and quality of life in patients with cancer. The feasibility of web-based assessments and data capture will be evaluated.

Timeline

Start
2003-10
Primary completion
2007-08-17
Completion
2007-08-17

Drugs

EvaluationDrugModalityDoseRoute
Comparator Darbepoetin alfa Protein / enzyme biologic 200 ug Subcutaneous
Comparator Darbepoetin alfa Protein / enzyme biologic 300 ug Subcutaneous
Comparator Darbepoetin alfa Protein / enzyme biologic 500 ug Subcutaneous

Indications